Potential molecular targets for narrow-spectrum agents to combat Mycoplasma pneumoniae infection and disease

Potential molecular targets for narrow-spectrum agents to combat Mycoplasma pneumoniae infection and disease

Blog Article

As Mycoplasma pneumoniae macrolide resistance grows and spreads worldwide, it is becoming more important to develop new drugs to prevent infection or limit disease.Because other mycoplasma species have acquired resistance to other classes of antibiotics, it is reasonable to presume that M.pneumoniae can do the same, so switching to commonly used antibiotics like fluoroquinolones will not result in forms of therapy with long-term utility.

Moreover, broad-spectrum antibiotics can have serious consequences for the patient, as these drugs may have severe impacts on the natural microbiota of the individual, PCB mount compromising the health of the patient either short-term or long-term.Therefore, developing narrow-spectrum antibiotics that effectively SHARK LIVER OIL target only M.pneumoniae and no more than a small portion of the microbiota is likely to yield impactful, positive results that can be used perhaps indefinitely to combat M.

pneumoniae.Development of these agents requires a deep understanding of the basic biology of M.pneumoniae, in many areas deeper than what is currently known.

In this review we discuss potential targets for new, narrow-spectrum agents and both the positive and negative aspects of selecting these targets, which include toxic molecules, metabolic pathways, and attachment and motility.By gathering this information together, we anticipate that it will be easier for researchers to evaluate topics of priority for study of M.pneumoniae.